Shinpoong Pharm
Update in progress019170.KS (KSE)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryDrug Manufacturers - Specialty & Generic
Shinpoong Pharmaceutical Co., Ltd., together with its subsidiaries, develops and sells a range of medicines in South Korea. Its products include cephalosporin and penicillin antibiotics, antivirals, anticancer drugs, pain relief, anti-inflammatories, and anthelmintics, plus APIs. It markets Pyramax (anti-malarial), therapies for high cholesterol, knee osteoarthritis, shoulder periarthritis, surgical adhesion barriers, prescription drugs, wound dressings, health foods, and OTC products. The company exports to about 50 countries and was founded in 1962 in Seoul.
Company score
- Sentiment
- 0.36
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.21
- Governance
- 0.11
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.08
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.22
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!